# Esperion Therapeutics

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/esperion-therapeutics/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | American pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320331660 |
| ROR ID | https://ror.org/019f2k932 |
| Works | 780 |

## Funder papers

- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study](https://scholariq.org/papers/the-effect-of-intravenous-ferric-carboxymaltose-on-health-related-quality-of/)
- [Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial](https://scholariq.org/papers/impact-of-oral-semaglutide-on-kidney-outcomes-in-people-with-type-2-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.